This review demonstrates connections between metabolic-associated steatotic liver disease and cardiovascular disease, suggesting a need for integrated approaches.
Metabolic-associated steatotic liver disease (MASLD) is a global health burden intricately linked to cardiovascular disease (CVD) through shared pathways-insulin resistance, dyslipidemia, and chronic inflammation. CVD has become the leading cause of mortality in MASLD, necessitating integrated management strategies. This review synthesizes evidence on bidirectional MASLD-CVD interactions and evaluates therapeutic approaches: Lifestyle modifications, pharmacotherapy (e.g. , GLP-1 receptor agonists, SGLT2 inhibitors, statins), and metabolic interventions. Despite progress, critical gaps persist in risk stratification tools, personalized treatment algorithms, and long-term outcomes of novel agents like resmetirom. A multidisciplinary care model, bridging hepatology and cardiology, is essential to address these challenges and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Luong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: